SCHEMBL7439477

SCHEMBL7439477

O=C(O)C1CCCCN1c1ccc(N2CCN(c3cccnc3)CC2)nc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.41
CPT2 P23786 1/20 0.41
CPT1A P50416 1/20 0.41
PIM1 P11309 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
HSD17B10 Q99714 1/20 0.39
GPR119 Q8TDV5 1/20 0.39
CHRNB2 P17787 2/20 0.39
CHRNA4 P43681 2/20 0.39
GRM5 P41594 1/20 0.39
CHRM4 P08173 1/20 0.38
BRS3 P32247 1/20 0.38
GFER P55789 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15665299 0.83 SMN1; SMN2 (0.52) SMN1; SMN2PIM1KMT2AKDM4EALDH1A1
SCHEMBL29507440 0.83 SMN1; SMN2 (0.52) SMN1; SMN2PIM1KMT2AKDM4EALDH1A1
SCHEMBL15665079 0.83 SMN1; SMN2 (0.52) SMN1; SMN2PIM1KMT2AKDM4EALDH1A1
SCHEMBL7399539 0.76 PORCN (0.49) SMN1; SMN2PIM1BRS3
SCHEMBL29290691 0.73 PIM1 (0.40) PIM1KMT2AKDM4EALDH1A1GPR119
SCHEMBL8104378 0.72 SMN1; SMN2 (0.46) SMN1; SMN2KMT2AALDH1A1HSD17B10BRS3
SCHEMBL13603832 0.72 SMN1; SMN2 (0.46) SMN1; SMN2KMT2AALDH1A1HSD17B10BRS3
SCHEMBL31173895 0.71 PIM1 (0.56) SMN1; SMN2PIM1ALDH1A1GPR119CHRNB2
SCHEMBL28570406 0.71 PIM1 (0.56) SMN1; SMN2PIM1ALDH1A1GPR119CHRNB2
SCHEMBL15664903 0.71 PIM1 (0.56) SMN1; SMN2PIM1ALDH1A1GPR119CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2002080920-A1 ARYLACETAMIDO-KETOBENZOXAZOLE AS CYSTEINE PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-10-17 WO claimed
US-20020156063-A1 Arylacetamido-ketobenzoxazole as cysteine protease inhibitors AXYS PHARMACEUTICALS, INC. 2002-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156063-A1 Arylacetamido-ketobenzoxazole as cysteine protease inhibitors SERPINB1, SPINT2, PRSS1 SMN1; SMN2 4367/4885CPT2 3151/4885CPT1A 1693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.